Indaptus Therapeutics (NASDAQ: INDP) furnishes Q3 2025 earnings press release

Rhea-AI Filing Summary

Indaptus Therapeutics, Inc. filed a current report to furnish a press release announcing its financial results for the quarter ended September 30, 2025. The company states that the full text of this earnings press release is provided as Exhibit 99.1 and is incorporated by reference. Indaptus clarifies that the information in this report, including the exhibit, is being furnished rather than filed, which limits its exposure to certain Exchange Act liabilities. The report is signed on behalf of the company by its Chief Financial Officer, Nir Sassi.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001857044 0001857044 2025-11-12 2025-11-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) November 12, 2025

INDAPTUS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-40652		86-3158720
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

3 Columbus Circle 15th Floor New York, New York		10019
(Address of principal executive offices)		(Zip Code)

(646) 427-2727

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.01 par value		INDP		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On November 12, 2025, Indaptus Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release of Indaptus Therapeutics, Inc., dated November 12, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 12, 2025

	INDAPTUS THERAPEUTICS, INC.
	By:	/s/ Nir Sassi
	Name:	Nir Sassi
	Title:	Chief Financial Officer

FAQ

What did Indaptus Therapeutics (INDP) disclose in this 8-K filing?

Indaptus Therapeutics disclosed that it issued a press release announcing financial results for the quarter ended September 30, 2025 and furnished that release as Exhibit 99.1.

Which period’s results does Indaptus Therapeutics (INDP) discuss in the attached press release?

The attached press release discusses Indaptus Therapeutics’ financial results for the quarter ended September 30, 2025.

How is the earnings press release treated under the Exchange Act in this Indaptus 8-K?

The company states that the information in this report, including Exhibit 99.1, is furnished and not deemed filed for purposes of Section 18 of the Exchange Act.

Where can investors find the detailed quarterly results for Indaptus Therapeutics (INDP)?

The detailed quarterly results are contained in the press release furnished as Exhibit 99.1 to this report.

Who signed this Indaptus Therapeutics (INDP) 8-K?

The report was signed on behalf of Indaptus Therapeutics, Inc. by Nir Sassi, its Chief Financial Officer.

What exhibits are included with this Indaptus Therapeutics (INDP) 8-K?

The filing includes Exhibit 99.1, a press release dated November 12, 2025, and Exhibit 104, the cover page interactive data file embedded in the Inline XBRL document.